Clinical trial
Open-Label Natalizumab Safety Extension Study
NCT00276172 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00276172 |
|---|---|
| Title | Open-Label Natalizumab Safety Extension Study |
| Official title | An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803 |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Natalizumab |
| Enrollment | 1,615 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Jan 13, 2006 |
| Last update posted | Jun 22, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: